10.6084/m9.figshare.5442370.v1
Prasad N.K.
Prasad
N.K.
Tandon M.
Tandon
M.
Handa A.
Handa
A.
Moore G.E.
Moore
G.E.
Babbs C.F.
Babbs
C.F.
Snyder P.W.
Snyder
P.W.
Bose S.
Bose
S.
Supplementary Material for: High Expression of Obesity-Linked Phosphatase SHIP2 in Invasive Breast Cancer Correlates with Reduced Disease-Free Survival
Karger Publishers
2017
Epidermal growth factor
Estrogen receptor status
Immunohistochemistry
Invasive carcinoma
Obesity
Phosphoinositol phosphatases
Primary breast cancers
PTEN
SHIP2
2017-09-26 13:46:45
Journal contribution
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_High_Expression_of_Obesity-Linked_Phosphatase_SHIP2_in_Invasive_Breast_Cancer_Correlates_with_Reduced_Disease-Free_Survival/5442370
<p>SH2-containing 5′-inositol phosphatase (SHIP2) is a known regulator
of insulin function. Genetic knockout of SHIP2 in mice causes mild
insulin hypersensitivity and prevents high-fat-diet-induced obesity.
SHIP2 also regulates actin remodeling and epidermal growth factor
receptor (EGFR) turnover and supports breast cancer; and metastatic
growth. To determine the clinical significance of SHIP2 expression in
breast cancer and its relationship to relevant oncogenic molecules,
SHIP2 expression was determined immunohistochemically in 285 primary
breast cancers; 140 ductal carcinomas in situ (DCIS) and 145 invasive
carcinomas. Forty-five percent of the specimens showed high SHIP2 levels
in cancer cells while only 15% of adjacent normal cells expressed high
SHIP2 levels (p < 0.0001). In cancer cells, the risk of SHIP2
overexpression is elevated (a) in women aged ≤50 years (relative risk,
RR = 4.13; 95% confidence interval, CI, 2.5–6.9) compared to women aged
>50 years (RR = 2.37; 95% CI 1.6–3.5; p = 0.0003), and (b) in
invasive carcinomas (RR = 3.52; 95% CI 2.3–5.5) compared with DCIS (RR =
2.22; 95% CI 1.5–3.5; p = 0.0009). Patients with higher SHIP2 levels in
invasive carcinomas had significantly reduced disease-free (p = 0.0025)
and overall survival periods (p = 0.0228). In invasive carcinomas,
SHIP2 correlated with estrogen receptor absence (p = 0.003) and EGFR
presence (p = 0.0147). In conclusion, SHIP2 is an important biomarker
for breast cancer.</p>